Exact Sciences sank -3.4% today, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Exact Sciences has moved 101.0% over the last year, and the S&P 500 logged a change of 19.0%
-
EXAS has an average analyst rating of buy and is -39.71% away from its mean target price of $111.47 per share
-
Its trailing earnings per share (EPS) is $-2.32
-
Exact Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -29.0 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $-1.08 and its forward P/E ratio is -62.2
-
The company has a Price to Book (P/B) ratio of 3.97 in contrast to the S&P 500's average ratio of 2.95
-
Exact Sciences is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
The company has a free cash flow of $-62333248, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.